Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03119805 · ClinicalTrials.gov registry record
Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.
A clinical trial of Psoriatic Arthritis, sponsored by Groupe Hospitalier Pitie-Salpetriere.
- Completed
- Registry status
- 466
- Enrollment target
- 20
- Study locations
NCT03119805: Completed study of Psoriatic Arthritis, sponsored by Groupe Hospitalier Pitie-Salpetriere.
NCT03119805 is a study of Psoriatic Arthritis that has completed, run by Groupe Hospitalier Pitie-Salpetriere. The registered enrollment target is 466 participants, below the 843-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (45% lower). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03119805, a study of Psoriatic Arthritis, has completed, sponsored by Groupe Hospitalier Pitie-Salpetriere.
- COMPLETED
- Registry status
- 466 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to define cut-off values of the most widely used composite scores and patient-reported outcomes, for levels corresponding to remission/low disease activity and for changes in levels corresponding to flares, in PsA, when remission/low disease activity and flare are defined from the patient and physician perspective. The ReFlaP (Remission/Flare in PsA) study is a prospective, multicentric international, longitudinal, observational study.
Primary Outcome
For flare, the gold standard will be decision of treatment intensification. The primary outcome will be to determine the cutoff value of PsAID corresponding flare. The PsAID is a questionnaire (paper CRF) that can be used to calculate a score reflecting the impact of psoriatic arthritis (PsA) from the patients' perspective. (Gossec L et al., A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis
Conditions Studied
Study Locations (20)
Other
- Smolen - Vienna
- Palominos - Porto Alegre
- Aydin - Ottawa
- Sibel Aydin - Ottawa
- Eder - Toronto
- Talli - Tallinn
- Soubrier - Clermont-Ferrand
- Dernis - Le Mans
- Laure Gossec - Paris
- Richette - Paris
- Ruyssen-Witrand - Toulouse
- Uta Kiltz - Herne
- Lubrano - Campobasso
- Rossana Scrivo - Roma
- Balanescu - Bucharest
- Inna Gaydukova - Saratov
- Katy Leung - Singapore
- Juan Canete - Barcelona
Maryland
- Ana- Maria Orbai - Baltimore
Ohio
- Husni - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 466 participants |
| Start Date | 2017-05-18 |
| Est. Completion | 2018-07-30 |
What the finished NCT03119805 record still lists
NCT03119805 is an observational study that tracks outcomes without assigning an intervention. The registered 466 participants enrollment target is mid-sized for trials with a published cap, below the 843-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (45% lower).
The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 0 interventions.
NCT03119805 names 20 study sites across 3 states, led by Other, Maryland, Ohio.
Frequently Asked Questions
What is clinical trial NCT03119805 about?
NCT03119805 is a clinical study titled "Remission and Flare in Psoriatic Arthritis: a Prospective 6-month Study With a Double Perspective.". The purpose of this study is to define cut-off values of the most widely used composite scores and patient-reported outcomes, for levels corresponding to remission/low disease activity and for changes in levels corresponding to flares, in PsA, when remission/low disease activity and flare are define...
What is the current status of trial NCT03119805?
This trial is currently completed. The enrollment target is 466 participants. The study started on 2017-05-18. Estimated completion is 2018-07-30.
What conditions does trial NCT03119805 study?
This clinical trial studies the following conditions: Psoriatic Arthritis.
Who is sponsoring clinical trial NCT03119805?
This trial is sponsored by Groupe Hospitalier Pitie-Salpetriere, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03119805 being conducted?
This trial has 20 study locations across Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriatic Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03119805's enrollment target sits among peer trials
466 18th of 48 higher than 31 of 48 other Psoriatic Arthritis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project
RECRUITING
-
Rheumatology Diet Study
RECRUITING
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
Stronger Together Psoriatic Arthritis Wellness Study
RECRUITING
-
A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab)
RECRUITING · Phase 1
-
Creating Health Course Study for People With Rheumatological Conditions
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05312879 · 466 participants · Phase 2
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1- Mediated Proteinuric Kidney Disease
- NCT06917404 · 466 participants · Phase 3
A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain.
- NCT07055165 · 466 participants · NA
Connect2Care: Prostate Cancer Education and Screenings for African American Men
- NCT07214779 · 466 participants · Phase 3
Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI